Dr. Lena Krzyzak
Lena joined High-Tech Gründerfonds (HTGF) in 2016 and is a Senior Investment Manager in the Life Science Team. She is currently responsible for several portfolio companies in the fields of medical technology, drug development, biotechnology and digital health as well as for sourcing and completion of new early-stage investments. Before, she worked as Postdoctoral Researcher at the University Hospital in Erlangen and obtained her PhD in Immunology within a DFG-funded Fast-track PhD program at the Friedrich-Alexander University Erlangen-Nürnberg. The thesis resulted in several publications in renowned journals. Lena received her Bachelor’s degree from the Georg-August University Göttingen with studies abroad in Umeå (Sweden) and Singapore.

Ulrich Mahr
As member of the General Management of Max-Planck-Innovation GmbH Ulrich oversees the technology transfer office´s spin-off activities and portfolio management. He advised and supported numerous start-up companies and served as chairman, member or observer on several advisory or supervisory boards. Ulrich took a leading role in establishing and financing several incubators and served as board member of ASTP, the European technology transfer association. He is jury member for the pre-seed grant scheme “EXIST Forschungstransfer“, member of the investment board for the regional venture fund “Wachstumsfonds Bayern“ and member of the advisory board of two start-up incubators. Following his diploma in business economics (Ludwig Maximilians University Munich) he initially worked for a leading IT distributor where he oversaw the Hewlett-Packard product portfolio with sales over €130m.

Dr. Detlev Mennerich
Detlev is Senior Investment Director at the Boehringer Ingelheim Venture Fund. Over the last six years, he led several investments of the therapeutics fund. He served as Board Member of ViraTherapeutics GmbH in Innsbruck, which was acquired by Boehringer Ingelheim in September 2018. Currently, Detlev serves at the Board of Imcheck Therapeutics in Marseilles, of Topas Therapeutics in Hamburg, of NBE Therapeutics in Basel, of T-Knife in Berlin, of Oncomyx in Phoenix, as well as of Tacalyx. In addition, he is member of the Strategic Committee of InnoBio II (BPI France) in Paris.
Detlev studied Chemistry in Braunschweig and Bordeaux and holds a PhD in Cell & Molecular Biology. In 2001, he started his industrial career at metaGen Pharmaceuticals and Schering AG in Berlin as a Scientist in Oncogenomics focusing on target validation and biomarker research. In 2005, he joined Boehringer Ingelheim in Biberach an der Riss, where he held several positions in Research: he started as Laboratory Head in Genomics for new drug concept nominations. In 2009, Detlev moved to Ridgefield, CT (USA) as Project Leader for an anti-inflammatory antibody project (which is currently in several Phase II trials). In 2011, he returned to Biberach heading the Target Validation Technologies Group supporting all diseases areas in new drug concept creation.
Beginning of 2014, he started as investment director at the Boehringer Ingelheim Venture Fund investing in clinical translation of pioneering therapeutic approaches, i.e. in the field of immuno-oncology, immuno-tolerization and regenerative concepts.

Dr. Peter Neubeck
Peter is a Medical Doctor, educated at Ludwig-Maximilians-Universität in Munich as well as Harvard Medical School and holds an MBA from INSEAD. After tenures at Großhadern University Clinic, Cleveland Clinic, and Beth Israel Deaconess Hospital followed by McKinsey & Company and several leadership positions at Novartis, he entered the Venture Capital industry. He took on responsibilities as an Investment Manager and collected valuable operational experience in various executive roles in company creations. Since January 2019 he heads the investment business of Kurma Partners in Germany.

Dr. Sebastian Pünzeler
Sebastian is Investment Manager and responsible for Life Science investments and portfolio management at coparion. He currently serves as a board member for Fasciotens GmbH, Protembis GmbH and Tacalyx GmbH. Before joining coparion in 2016, Sebastian started his VC career at Gimv in Munich. Sebastian holds a diploma in Biology from the RWTH Aachen University / the LMU Munich and a PhD in Molecular Biology from the International Max Planck Research School for Molecular Life Sciences (IMPRS-LS) Munich. His research resulted in several publications in renowned journals.

Karlheinz Schmelig
Karlheinz is a Managing Partner at Creathor Ventures focusing on life sciences and healthtech investments. He has a broad background in private equity and venture capital and has been working in the industry for nearly 20 years.
Before joining Creathor, Karlheinz worked as an investment director at 3i Group plc and before that as an investment manager at the Technologieholding VC GmbH. Prior to his venture capital career Karlheinz worked successfully for over ten years in a number of global management positions in the healthcare industry. He spent seven of these years in the US at Boehringer Mannheim and F. Hoffmann-La Roche, where he worked in global business development and marketing roles.
Karlheinz studied business in Mannheim and received a Master of Business Administration (MBA) from the Kelly School of Business at Indiana University. He is also a member of the Beta Gamma Sigma Honor Society for Business Administration and a Certified Production Inventory Manager (CPIM) with the American Production and Inventory Control Society (APICS). He currently serves as an advisory board member for the “GO BIO Gründerinitiative” of the German Federal Ministry of Education and Research (BMBF) and is a member of the Venture Council of Invest Europe.

Dr. Klaus Schollmeier
Klaus is an advisor to the Pharma/Biotech industry and member of the board/chairman of several Biotech companies including Anergis Pharma (Switzerland), Affiris Pharma (Austria) and Eternygen (Germany). He also advises and mentors a number of start-up companies in Europe as entrepreneur in residence and business angel. Klaus was Chief Executive Officer of SuppreMol (Germany) from 2013 until 2015, when the company was sold to Baxter. Prior to that, he served as CEO of Santhera (Switzerland), from 2004 to 2011 and chairman of the board of Santhera until 2013. Klaus joined Graffinity Pharmaceuticals AG (Germany) as CEO in 2003 and merged the company with MyoContract AG (Switzerland) in 2004 to form Santhera. Before joining the biotechnology industry in 2003, he served as managing director of the healthcare/biotechnology group at ING-BHF Bank for ING Group Europe. Prior to that, he spent 16 years in the pharmaceutical industry at BASF, Knoll and Abbott. His scientific responsibilities included head of oncology/immunology research at BASF’s central laboratories in Ludwigshafen, Germany, and senior director of biotechnology at BASF Bioresearch Corporation in Cambridge, Massachusetts, USA (from 1989 to 1993). His business functions included general manager of BASF Pharma Netherlands from 1996 to 1998 and vice president and general manager for Western Europe thereafter. From 1994 to 1995, he led BASF’s acquisition and integration of Boots Pharmaceuticals.
Klaus holds a PhD in biology from the University of Düsseldorf (Germany) and in 1991 he became an adjunct research associate professor at the Boston University Medical School, Massachusetts.

Prof. Dr. Peter Seeberger
Peter is cofounder and member of the board of Tacalyx. He is director at the Max-Planck Institute for Colloids and Surfaces in Potsdam. His research focus is on the chemistry and biology of carbohydrates ranging from synthesis to immunology and he has a long track record of translating cutting-edge basic research into products. His research has been documented in more than 500 journal articles, more than 50 patents and has been recognized by more than 40 international awards.